New
York City, 2 Nov 2020: The
global platelet aggregation devices market size is expected to
reach USD 1,556.8 million by 2027 according to a new study by Polaris Market
Research. Platelet aggregation is the biological process where the platelet
cells are employed in a process to prevent bleeding through vaso-constriction
for rapid clot formation. The whole process is mediated via platelet aggregating
factor (PAF). The quantitative and qualitative defects of platelets lead to
increased bleeding. The high reactivity of platelets in the patients having
anti-platelet therapy results in thromboembolic complications.
Platelet function related disorders can be either
inherited or acquired. The inherited platelet function disorders include Von
Willebrand disease, Glanzmann’s thrombasthenia, Bernard-Soulier syndrome,
Storage pool disease. The acquired platelet dysfunction may be caused by
chronic conditions such as kidney failure (uremia), Myelodysplastic syndrome
(MDS), Leukemias (chronic myeloid leukemia or CML; acute myeloid leukemia or
AML).
 |
| Know more about this report: request for sample pages |
Some acquired platelet disorders are temporary because of the decreased function of platelets due to anti-platelet medications, non-steroidal anti-inflammatory drugs (NSAIDs), tricyclic antidepressants, antihistamines and some antibiotics. The platelet function testing is transitioned from diagnostics for heritable diseases to a functional one for platelet functional therapies. The rapid usage of anti-platelet therapy, mainly dual anti-platelet therapy has changed the focus of platelet function testing from diagnostics to therapeutics. The market is driven by few notable factors such as the recent surge in infectious diseases (COVID-19) requiring rapid serological tests, innovations in platelet aggregation mechanisms, systems and consumables, and worldwide rise in chronic ailments. Specialized tests based on platelet aggregation include light transmission platelet aggregometry on platelet-rich plasma (LTA), impedance whole blood aggregometry (WBA), Lumi-aggregometry and flow cytometry.
Automated haematology analyzers can be used to
obtain platelet counts over a wide range of values using optical counting
methods like light scatter or fluorescence. Screening tests such as prothrombin
time (PT) or activated partial thromboplastin time (aPTT) are more standardized
and fully automated.
Number of reagents are available in the market to
carry out the platelet function tests. These reagents include collagen,
thrombin, ADP, vasopressin, epinephrine and ristocetin. Collagen, ADP were used
in routine platelet aggregation studies for the evaluation of qualitative
platelet function disorders.
Market participants such as F. Hoffmann La-Roche Ltd.,
Drucker Diagnostics, Haemonetics Corporation, Sysmex Corporation, Siemens
Healthineers, Chrono-log Corporation, Instrumentation Laboratory, Accriva
Diagnostics, Matis Medical, Helena Laboratories Corporation, Sienco, Inc.,
Bio/Data Corporation, Tem Group, WerfenLife, S.A., Laboratory Corporation of
America Holdings, Sentinel CH. S.p.A., and Aggredyne, Inc. are some of the key
players operating in the concerned market.
No comments:
Post a Comment